Trinity Biotech | TRIB

Trinity Biotech traded at $0.92 this Wednesday March 22nd, decreasing $0.0001 or 0.01 percent since the previous trading session. Looking back, over the last four weeks, Trinity Biotech lost 15.60 percent. Over the last 12 months, its price fell by 14.42 percent. Looking ahead, we forecast Trinity Biotech to be priced at 0.84 by the end of this quarter and at 0.75 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.92
Daily Change
-0.01%
Yearly
-14.42%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Tosoh 1,764.00 24.00 1.38% -5.92%
Abbott 98.92 0.59 0.60% -15.40%
Bayer 57.02 -0.16 -0.28% -4.06%
Bio-Rad Laboratories 477.45 -2.84 -0.59% -15.55%
Plus Therapeutics, Inc. 0.28 0.01 2.75% -72.82%
EDAP TMS 11.46 0.23 2.09% 59.45%
J&J 152.99 -0.90 -0.58% -12.25%
Mesa Laboratories 171.80 -2.33 -1.34% -31.10%
OraSure Technologies 5.98 -0.07 -1.16% -14.69%
Roche Holding 262.20 -0.50 -0.19% -28.27%
Siemens 145.76 2.98 2.09% 11.27%
Sientra 1.46 -0.02 -1.35% -40.65%
Surmodics 17.50 -0.18 -1.02% -57.59%
Thermo Fisher Scientific 563.10 6.40 1.15% -1.44%
Trinity Biotech 0.92 -0.0001 -0.01% -14.42%
Veracyte 23.23 -0.01 -0.04% -17.51%

Indexes Price Day Year
USND 11895 35.14 0.30% -14.56%

Trinity Biotech
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.